Outlook Therapeutics, Inc. (NASDAQ:OTLK) recovered 125.88% of its value since hitting low of $0.85. The recent move of -4.95% drop pushed the stock to close at $1.92 when trading ended on 6/11/2019. At a recent session, the prices were hovering between $1.9 and $2.03. This company shares are 108.33% off its target price of $4 and the current market capitalization stands at $48.21M. The recent change has given its price a -23.54% deficit over SMA 50 and -82.48% deficit over its 52-week high. The stock witnessed 60% gains, -74.2% declines and -62.53% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found OTLK’s volatility during a week at 12.49% and during a month it has been found around 20.44%.

Outlook Therapeutics, Inc. 13F Filings

At the end of March reporting period, 8 institutional holders increased their position in Outlook Therapeutics, Inc. (NASDAQ:OTLK) by some 64,514 shares, 10 decreased positions by 396,705 and 1 held positions by -255,144. That puts total institutional holdings at 206,075 shares, according to SEC filings. The stock grabbed 7 new institutional investments totaling 64,351 shares while 6 institutional investors sold out their entire positions totaling 394,367 shares.

Outlook Therapeutics, Inc. (NASDAQ:OTLK) Insider Trades

Multiple company employees have indulged in significant insider trading. Outlook Therapeutics, Inc. disclosed in a document filed with the US Securities and Exchange Commission (SEC) that CEO, Pres, CFO, Treas & Secy KENYON LAWRENCE A has acquired 25,000 shares of Outlook Therapeutics, Inc. (OTLK) in the trading session dated Feb. 07, 2019. These shares are worth $22,500 and were traded at $0.9 each. The SEC filing shows that HILZINGER KURT J performed a purchase of 5,983 shares. The Director added these shares by way of transaction on Feb. 04, 2019. The company’s shares were assimilated at $0.8 per share worth to an investment of some $4,786 to the account of HILZINGER KURT J.

Director, HILZINGER KURT J, purchased 19,390 common shares of Outlook Therapeutics, Inc. (OTLK) in the open market. In a transaction dated Feb. 01, 2019, the shares were bought at an average price of $0.75, giving away a sum of $14,543. After this purchase, 178,964 common shares of OTLK are directly owned by the insider, with total stake valued at $343,611.

In the transaction dated Jan. 29, 2019, a great number of shares acquired came courtesy the Director; HILZINGER KURT J added a total of 32,112 shares at an average price of $0.71, amounting to approximately $22,800. The insider now directly owns 159,574 shares worth $306,382.

Outlook Therapeutics, Inc. (OTLK) Analyst Guide

Not many analysts have released their opinion on Outlook Therapeutics, Inc. (NASDAQ:OTLK), with 1 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 1 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.5 average brokerage recommendation [T1].